HSBC lowered the firm’s price target on Illumina to $170 from $230 and keeps a Buy rating on the shares. The challenging macro environment, biotech funding impact, China softness and COVID-19 unwind are headwinds for the diagnostics sector, the analyst tells investors in a research note. However, the firm says multiples have de-rated and it likes players with earnings momentum, namely Biomerieux and Qiagen.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ILMN:
- Illumina put volume heavy and directionally bearish
- Illumina price target lowered to $200 from $225 at Stifel
- Illumina price target lowered to $100 from $150 at Barclays
- Illumina initiated with an Underperform at Bernstein
- Myriad Genetics, Illumina achieve milestones in strategic partnership
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue